dreamproit/uscode huggingface dataset:
15 U.S.C. § 7451 (COMMERCE AND TRADE)
§ 7451. Transferred
heading: Editorial Notes
heading: Codification
text: Section, Pub. L. 113–274, title IV, § 401, Dec. 18, 2014, 128 Stat. 2985, which related to national cybersecurity awareness and education program, was renumbered § 303 of title III of Pub. L. 113–274, by Pub. L. 116–283, div. H, title XCIV, § 9401(g)(1), Jan. 1, 2021, 134 Stat. 4809, and transferred to section 7443 of this title.
15 U.S.C. § 7502 (COMMERCE AND TRADE)
§ 7502. Program coordination
(a) In general
The President shall establish a National Nanotechnology Coordination Office, with a Director and full-time staff, which shall—
(1) provide technical and administrative support to the Council and the Advisory Panel;
(2) serve as the point of contact on Federal nanotechnology activities for government organizations, academia, industry, professional societies, State nanotechnology programs, interested citizen groups, and others to exchange technical and programmatic information;
(3) conduct public outreach, including dissemination of findings and recommendations of the Advisory Panel, as appropriate; and
(4) promote access to and early application of the technologies, innovations, and expertise derived from Program activities to agency missions and systems across the Federal Government, and to United States industry, including startup companies.
(b) Funding
The National Nanotechnology Coordination Office shall be funded through interagency funding in accordance with section 631 of Public Law 108–7.
(c) Report
Within 90 days after December 3, 2003, the Director of the Office of Science and Technology Policy shall report to the Senate Committee on Commerce, Science, and Transportation, and the House of Representatives Committee on Science on the funding of the National Nanotechnology Coordination Office. The report shall include—
(1) the amount of funding required to adequately fund the Office;
(2) the adequacy of existing mechanisms to fund this Office; and
(3) the actions taken by the Director to ensure stable funding of this Office.
(Pub. L. 108–153, § 3, Dec. 3, 2003, 117 Stat. 1926.)
heading: Editorial Notes
heading: References in Text
text: Section 631 of Public Law 108–7, referred to in subsec. (b), is section 631 of Pub. L. 108–7, div. J, title VI, Feb. 20, 2003, 117 Stat. 471, which is not classified to the Code.
heading: Statutory Notes and Related Subsidiaries
heading: Change of Name
text: Committee on Science of House of Representatives changed to Committee on Science and Technology of House of Representatives by House Resolution No. 6, One Hundred Tenth Congress, Jan. 5, 2007. Committee on Science and Technology of House of Representatives changed to Committee on Science, Space, and Technology of House of Representatives by House Resolution No. 5, One Hundred Twelfth Congress, Jan. 5, 2011.
15 U.S.C. § 7506 (COMMERCE AND TRADE)
§ 7506. Department of Commerce programs
(a) NIST programs
The Director of the National Institute of Standards and Technology shall—
(1) as part of the Program activities under section 7501(b)(7) of this title, establish a program to conduct basic research on issues related to the development and manufacture of nanotechnology, including metrology; reliability and quality assurance; processes control; and manufacturing best practices; and
(2) utilize the Manufacturing Extension Partnership program 1 to the extent possible to ensure that the research conducted under paragraph (1) reaches small- and medium-sized manufacturing companies.
(b) Clearinghouse
The Secretary of Commerce or his designee, in consultation with the National Nanotechnology Coordination Office and, to the extent possible, utilizing resources at the National Technical Information Service, shall establish a clearinghouse of information related to commercialization of nanotechnology research, including information relating to activities by regional, State, and local commercial nanotechnology initiatives; transition of research, technologies, and concepts from Federal nanotechnology research and development programs into commercial and military products; best practices by government, universities and private sector laboratories transitioning technology to commercial use; examples of ways to overcome barriers and challenges to technology deployment; and use of manufacturing infrastructure and workforce.
(Pub. L. 108–153, § 7, Dec. 3, 2003, 117 Stat. 1930.)
heading: Statutory Notes and Related Subsidiaries
heading: Change of Name
text: The Manufacturing Extension Partnership Program, referred to in subsec. (a), redesignated the Hollings Manufacturing Partnership Program by a provision of title II of div. B of Pub. L. 108–447, formerly set out as a note under section 278k of this title. Program subsequently designated the Hollings Manufacturing Extension Partnership by former section 278k(i) of this title, as added by Pub. L. 111–358, and by section 278k of this title, as generally amended by Pub. L. 114–329.
15 U.S.C. § 7508 (COMMERCE AND TRADE)
§ 7508. Additional centers
(a) American Nanotechnology Preparedness Center
The Program shall provide for the establishment, on a merit-reviewed and competitive basis, of an American Nanotechnology Preparedness Center which shall—
(1) conduct, coordinate, collect, and disseminate studies on the societal, ethical, environmental, educational, legal, and workforce implications of nanotechnology; and
(2) identify anticipated issues related to the responsible research, development, and application of nanotechnology, as well as provide recommendations for preventing or addressing such issues.
(b) Center for nanomaterials manufacturing
The Program shall provide for the establishment, on a merit reviewed and competitive basis, of a center to—
(1) encourage, conduct, coordinate, commission, collect, and disseminate research on new manufacturing technologies for materials, devices, and systems with new combinations of characteristics, such as, but not limited to, strength, toughness, density, conductivity, flame resistance, and membrane separation characteristics; and
(2) develop mechanisms to transfer such manufacturing technologies to United States industries.
(c) Reports
The Council, through the Director of the National Nanotechnology Coordination Office, shall submit to the Senate Committee on Commerce, Science, and Transportation and the House of Representatives Committee on Science—
(1) within 6 months after December 3, 2003, a report identifying which agency shall be the lead agency and which other agencies, if any, will be responsible for establishing the Centers described in this section; and
(2) within 18 months after December 3, 2003, a report describing how the Centers described in this section have been established.
(Pub. L. 108–153, § 9, Dec. 3, 2003, 117 Stat. 1930.)
heading: Statutory Notes and Related Subsidiaries
heading: Change of Name
text: Committee on Science of House of Representatives changed to Committee on Science and Technology of House of Representatives by House Resolution No. 6, One Hundred Tenth Congress, Jan. 5, 2007. Committee on Science and Technology of House of Representatives changed to Committee on Science, Space, and Technology of House of Representatives by House Resolution No. 5, One Hundred Twelfth Congress, Jan. 5, 2011.
15 U.S.C. § 7601 (COMMERCE AND TRADE)
§ 7601. Availability of contact lens prescriptions to patients
(a) In general
When a prescriber completes a contact lens fitting, the prescriber—
(1) whether or not requested by the patient, shall provide to the patient a copy of the contact lens prescription; and
(2) shall, as directed by any person designated to act on behalf of the patient, provide or verify the contact lens prescription by electronic or other means.
(b) Limitations
A prescriber may not—
(1) require purchase of contact lenses from the prescriber or from another person as a condition of providing a copy of a prescription under subsection (a)(1) or (a)(2) or verification of a prescription under subsection (a)(2);
(2) require payment in addition to, or as part of, the fee for an eye examination, fitting, and evaluation as a condition of providing a copy of a prescription under subsection (a)(1) or (a)(2) or verification of a prescription under subsection (a)(2); or
(3) require the patient to sign a waiver or release as a condition of verifying or releasing a prescription.
(Pub. L. 108–164, § 2, Dec. 6, 2003, 117 Stat. 2024.)
heading: Statutory Notes and Related Subsidiaries
heading: Effective Date
text: Pub. L. 108–164, § 12, Dec. 6, 2003, 117 Stat. 2028, provided that: “This Act [enacting this chapter and provisions set out as a note below] shall take effect 60 days after the date of the enactment of this Act [Dec. 6, 2003].”
heading: Short Title
text: Pub. L. 108–164, § 1, Dec. 6, 2003, 117 Stat. 2024, provided that: “This Act [enacting this chapter and provisions set out as a note above] may be cited as the ‘Fairness to Contact Lens Consumers Act’.”
15 U.S.C. § 7602 (COMMERCE AND TRADE)
§ 7602. Immediate payment of fees in limited circumstances
A prescriber may require payment of fees for an eye examination, fitting, and evaluation before the release of a contact lens prescription, but only if the prescriber requires immediate payment in the case of an examination that reveals no requirement for ophthalmic goods. For purposes of the preceding sentence, presentation of proof of insurance coverage for that service shall be deemed to be a payment.
(Pub. L. 108–164, § 3, Dec. 6, 2003, 117 Stat. 2024.)
heading: Statutory Notes and Related Subsidiaries
heading: Effective Date
text: Section effective 60 days after Dec. 6, 2003, see section 12 of Pub. L. 108–164, set out as a note under section 7601 of this title.
15 U.S.C. § 7603 (COMMERCE AND TRADE)
§ 7603. Prescriber verification
(a) Prescription requirement
A seller may sell contact lenses only in accordance with a contact lens prescription for the patient that is—
(1) presented to the seller by the patient or prescriber directly or by facsimile; or
(2) verified by direct communication.
(b) Record requirement
A seller shall maintain a record of all direct communications referred to in subsection (a).
(c) Information
When seeking verification of a contact lens prescription, a seller shall provide the prescriber with the following information:
(1) Patient’s full name and address.
(2) Contact lens power, manufacturer, base curve or appropriate designation, and diameter when appropriate.
(3) Quantity of lenses ordered.
(4) Date of patient request.
(5) Date and time of verification request.
(6) Name of contact person at seller’s company, including facsimile and telephone number.
(d) Verification events
A prescription is verified under this chapter only if one of the following occurs:
(1) The prescriber confirms the prescription is accurate by direct communication with the seller.
(2) The prescriber informs the seller that the prescription is inaccurate and provides the accurate prescription.
(3) The prescriber fails to communicate with the seller within 8 business hours, or a similar time as defined by the Federal Trade Commission, after receiving from the seller the information described in subsection (c).
(e) Invalid prescription
If a prescriber informs a seller before the deadline under subsection (d)(3) that the contact lens prescription is inaccurate, expired, or otherwise invalid, the seller shall not fill the prescription. The prescriber shall specify the basis for the inaccuracy or invalidity of the prescription. If the prescription communicated by the seller to the prescriber is inaccurate, the prescriber shall correct it.
(f) No alteration
A seller may not alter a contact lens prescription. Notwithstanding the preceding sentence, if the same contact lens is manufactured by the same company and sold under multiple labels to individual providers, the seller may fill the prescription with a contact lens manufactured by that company under another label.
(g) Direct communication
As used in this section, the term “direct communication” includes communication by telephone, facsimile, or electronic mail.
(Pub. L. 108–164, § 4, Dec. 6, 2003, 117 Stat. 2024.)
heading: Statutory Notes and Related Subsidiaries
heading: Effective Date
text: Section effective 60 days after Dec. 6, 2003, see section 12 of Pub. L. 108–164, set out as a note under section 7601 of this title.
15 U.S.C. § 7604 (COMMERCE AND TRADE)
§ 7604. Expiration of contact lens prescriptions
(a) In general
A contact lens prescription shall expire—
(1) on the date specified by the law of the State in which the prescription was written, if that date is one year or more after the issue date of the prescription;
(2) not less than one year after the issue date of the prescription if such State law specifies no date or a date that is less than one year after the issue date of the prescription; or
(3) notwithstanding paragraphs (1) and (2), on the date specified by the prescriber, if that date is based on the medical judgment of the prescriber with respect to the ocular health of the patient.
(b) Special rules for prescriptions of less than 1 year
If a prescription expires in less than 1 year, the reasons for the judgment referred to in subsection (a)(3) shall be documented in the patient’s medical record. In no circumstance shall the prescription expiration date be less than the period of time recommended by the prescriber for a reexamination of the patient that is medically necessary.
(c) Definition
As used in this section, the term “issue date” means the date on which the patient receives a copy of the prescription.
(Pub. L. 108–164, § 5, Dec. 6, 2003, 117 Stat. 2025.)
heading: Statutory Notes and Related Subsidiaries
heading: Effective Date
text: Section effective 60 days after Dec. 6, 2003, see section 12 of Pub. L. 108–164, set out as a note under section 7601 of this title.
15 U.S.C. § 7605 (COMMERCE AND TRADE)
§ 7605. Content of advertisements and other representations
Any person that engages in the manufacture, processing, assembly, sale, offering for sale, or distribution of contact lenses may not represent, by advertisement, sales presentation, or otherwise, that contact lenses may be obtained without a prescription.
(Pub. L. 108–164, § 6, Dec. 6, 2003, 117 Stat. 2026.)
heading: Statutory Notes and Related Subsidiaries
heading: Effective Date
text: Section effective 60 days after Dec. 6, 2003, see section 12 of Pub. L. 108–164, set out as a note under section 7601 of this title.
15 U.S.C. § 7606 (COMMERCE AND TRADE)
§ 7606. Prohibition of certain waivers
A prescriber may not place on the prescription, or require the patient to sign, or deliver to the patient a form or notice waiving or disclaiming the liability or responsibility of the prescriber for the accuracy of the eye examination. The preceding sentence does not impose liability on a prescriber for the ophthalmic goods and services dispensed by another seller pursuant to the prescriber’s correctly verified prescription.
(Pub. L. 108–164, § 7, Dec. 6, 2003, 117 Stat. 2026.)
heading: Statutory Notes and Related Subsidiaries
heading: Effective Date
text: Section effective 60 days after Dec. 6, 2003, see section 12 of Pub. L. 108–164, set out as a note under section 7601 of this title.
15 U.S.C. § 7607 (COMMERCE AND TRADE)
§ 7607. Rulemaking by Federal Trade Commission
The Federal Trade Commission shall prescribe rules pursuant to section 57a of this title to carry out this chapter. Rules so prescribed shall be exempt from the requirements of the Magnuson-Moss Warranty—Federal Trade Commission Improvement Act (15 U.S.C. 2301 et seq.). Any such regulations shall be issued in accordance with section 553 of title 5. The first rules under this section shall take effect not later than 180 days after the effective date of this chapter.
(Pub. L. 108–164, § 8, Dec. 6, 2003, 117 Stat. 2026.)
heading: Editorial Notes
heading: References in Text
text: The Magnuson-Moss Warranty—Federal Trade Commission Improvement Act, referred to in text, is Pub. L. 93–637, Jan. 4, 1975, 88 Stat. 2183, as amended. Title I of the Act is classified generally to chapter 50 (§ 2301 et seq.) of this title. For complete classification of this Act to the Code, see Short Title note set out under section 2301 of this title and Tables.
For effective date of this chapter, referred to in text, see section 12 of Pub. L. 108–164, set out as an Effective Date note under section 7601 of this title.
heading: Statutory Notes and Related Subsidiaries
heading: Effective Date
text: Section effective 60 days after Dec. 6, 2003, see section 12 of Pub. L. 108–164, set out as a note under section 7601 of this title.
15 U.S.C. § 7608 (COMMERCE AND TRADE)
§ 7608. Violations
(a) In general
Any violation of this chapter or the rules required under section 7607 of this title shall be treated as a violation of a rule under section 18 of the Federal Trade Commission Act (15 U.S.C. 57a) regarding unfair or deceptive acts or practices.
(b) Actions by the Commission
The Federal Trade Commission shall enforce this chapter in the same manner, by the same means, and with the same jurisdiction, powers, and duties as though all applicable terms and provisions of the Federal Trade Commission Act (15 U.S.C. 41 et seq.) were incorporated into and made a part of this chapter.
(Pub. L. 108–164, § 9, Dec. 6, 2003, 117 Stat. 2026.)
heading: Editorial Notes
heading: References in Text
text: The Federal Trade Commission Act, referred to in subsec. (b), is act Sept. 26, 1914, ch. 311, 38 Stat. 717, as amended, which is classified generally to subchapter I (§ 41 et seq.) of chapter 2 of this title. For complete classification of this Act to the Code, see section 58 of this title and Tables.
heading: Statutory Notes and Related Subsidiaries
heading: Effective Date
text: Section effective 60 days after Dec. 6, 2003, see section 12 of Pub. L. 108–164, set out as a note under section 7601 of this title.
15 U.S.C. § 7609 (COMMERCE AND TRADE)
§ 7609. Study and report
(a) Study
The Federal Trade Commission shall undertake a study to examine the strength of competition in the sale of prescription contact lenses. The study shall include an examination of the following issues:
(1) Incidence of exclusive relationships between prescribers or sellers and contact lens manufacturers and the impact of such relationships on competition.
(2) Difference between online and offline sellers of contact lenses, including price, access, and availability.
(3) Incidence, if any, of contact lens prescriptions that specify brand name or custom labeled contact lenses, the reasons for the incidence, and the effect on consumers and competition.
(4) The impact of the Federal Trade Commission eyeglasses rule (16 CFR 456 et seq.) on competition, the nature of the enforcement of the rule, and how such enforcement has impacted competition.
(5) Any other issue that has an impact on competition in the sale of prescription contact lenses.
(b) Report
Not later than 12 months after the effective date of this chapter, the Chairman of the Federal Trade Commission shall submit to the Congress a report of the study required by subsection (a).
(Pub. L. 108–164, § 10, Dec. 6, 2003, 117 Stat. 2026.)
heading: Editorial Notes
heading: References in Text
text: For effective date of this chapter, referred to in subsec. (b), see section 12 of Pub. L. 108–164, set out as an Effective Date note under section 7601 of this title.
heading: Statutory Notes and Related Subsidiaries
heading: Effective Date
text: Section effective 60 days after Dec. 6, 2003, see section 12 of Pub. L. 108–164, set out as a note under section 7601 of this title.
15 U.S.C. § 7610 (COMMERCE AND TRADE)
§ 7610. Definitions
As used in this chapter:
(1) Contact lens fitting
The term “contact lens fitting” means the process that begins after the initial eye examination and ends when a successful fit has been achieved or, in the case of a renewal prescription, ends when the prescriber determines that no change in prescription is required, and such term may include—
(A) an examination to determine lens specifications;
(B) except in the case of a renewal of a prescription, an initial evaluation of the fit of the lens on the eye; and
(C) medically necessary follow up examinations.
(2) Prescriber
The term “prescriber” means, with respect to contact lens prescriptions, an ophthalmologist, optometrist, or other person permitted under State law to issue prescriptions for contact lenses in compliance with any applicable requirements established by the Food and Drug Administration.
(3) Contact lens prescription
The term “contact lens prescription” means a prescription, issued in accordance with State and Federal law, that contains sufficient information for the complete and accurate filling of a prescription, including the following:
(A) Name of the patient.
(B) Date of examination.
(C) Issue date and expiration date of prescription.
(D) Name, postal address, telephone number, and facsimile telephone number of prescriber.
(E) Power, material or manufacturer or both.
(F) Base curve or appropriate designation.
(G) Diameter, when appropriate.
(H) In the case of a private label contact lens, name of manufacturer, trade name of private label brand, and, if applicable, trade name of equivalent brand name.
(Pub. L. 108–164, § 11, Dec. 6, 2003, 117 Stat. 2027.)
heading: Statutory Notes and Related Subsidiaries
heading: Effective Date
text: Section effective 60 days after Dec. 6, 2003, see section 12 of Pub. L. 108–164, set out as a note under section 7601 of this title.